6 completed, 4 not yet recruiting, 2 recruiting, 1 enrolling by invitation. 7 Not applicable, 2 Phase 2, 1 Early Phase 1, 1 Phase 3, 1 Phase 4.
Follow Hyperlipidaemia: new trials by email Literature Review of Hyperlipidaemia trials Research Report on Hyperlipidaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health (Healthy Heart - CKM) Team-based shared decision-making - Hypertension (HTN), Diabetes (DM) | Early Phase 1 | Not yet recruiting | Johns Hopkins University | 94 | 2026-10-30 | 2026-10-19 |
| Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 100 | 2026-08-01 | 2026-08-13 |
| Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies Pharmacist-led diabetes care pathway - Diabetes Mellitus, Hypertension | Not applicable | Recruiting | University of Alberta | 600 | 2025-10-13 | 2026-01-14 |
| Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease. The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS, Placebo Drug - MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus | Phase 2 | Not yet recruiting | Eva Cubric | 114 | 2025-07-01 | 2025-06-18 |
| Developing an AI Pharmacy Chatbot for the Population of Hong Kong An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia - Hyperglycaemia, Hypertension | Not applicable | Recruiting | The University of Hong Kong | 280 | 2025-06-01 | 2025-06-25 |
| Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland myCare Start - Cardio-vascular Disease, Depression Disorders | Not applicable | Not yet recruiting | University of Geneva, Switzerland | 1600 | 2025-06-01 | 2025-06-25 |
| Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in Bogotá High-oleic palm oil - Insulinemic Response, Type 2 Diabetes (Adult Onset) | Not applicable | Completed | Ruby Alejandra Villamil | 52 | 2024-10-22 | 2026-08-05 |
| Therapeutic Effects of Cinnamon-Enriched Cookies on Hypercholesterolemia and Liver Function Treatment group T1 - Hyperlipidaemia, Liver Biomarkers | Not applicable | Completed | University of Lahore | 40 | 2024-05-02 | 2026-07-31 |
| Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas Cardiovascular Abnormalities, Arterial Blood Pressure | Enrolling by invitation | Laikο General Hospital, Athens | 50 | 2024-02-05 | 2026-01-05 | |
| Effects of Olive Oil and MLCT on Glycolipid Homeostasis in Patients With Metabolic Syndrome Olive oil use, MLCT oil use - Hyperlipidaemia, Metabolic Syndrome | Not applicable | Completed | Zhejiang University | 240 | 2023-06-09 | 2024-11-15 |
| Nigella Sativa Supplementation in Hyperlipidemia Treatment Nigella Sativa Oil capsule, Diet - Hyperlipidaemia, Hyperlipidemia | Not applicable | Completed | Istanbul Bilgi University | 64 | 2023-06-01 | 2025-03-24 |
| A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia AZD8233, Placebo - Hyperlipidaemia | Phase 2 | Completed | AstraZeneca | 411 | 2021-07-07 | 2023-12-15 |
| TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060) MK-0653, ezetimibe, Duration of Treatment: 3 months - Hypercholesterolaemia, Hyperlipidaemia | Phase 3 | Completed | Organon and Co | 1496 | 2004-06-01 | 2024-08-15 |
Hyperlipidemias (13) · Diabetes Mellitus (5) · Hypertension (4) · Hypercholesterolemia (2) · Hyperglycemia (2) · Metabolic Syndrome (2) · Obesity (2) · Angina, Unstable (1) · Body Weight Changes (1) · Cardiovascular Abnormalities (1) · Cerebrovascular Disorders (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 2 (1) · Hypertriglyceridemia (1) · Kidney Diseases (1)
Dyslipidemias (13) · Lipid Metabolism Disorders (13) · Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Glucose Metabolism Disorders (8) · Cardiovascular Diseases (6) · Endocrine System Diseases (6) · Vascular Diseases (6) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (4) · Body Weight (3) · Heart Diseases (2) · Hyperinsulinism (2) · Insulin Resistance (2) · Myocardial Ischemia (2)
Diet (1) · Duration of Therapy (1) · Ezetimibe (1) · Nigella sativa oil (1) · eicosapentaenoic acid ethyl ester (1)
AstraZeneca (1) · China National Center for Cardiovascular Diseases (1) · Eva Cubric (1) · Istanbul Bilgi University (1) · Johns Hopkins University (1) · Laikο General Hospital, Athens (1) · Organon and Co (1) · Ruby Alejandra Villamil (1) · The University of Hong Kong (1) · University of Alberta (1) · University of Geneva, Switzerland (1) · University of Lahore (1) · Zhejiang University (1)
China (2) · Canada (1) · Colombia (1) · Croatia (1) · Czechia (1) · Denmark (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Slovakia (1) · Spain (1) · Switzerland (1)
Cheryl Himmelfarb, PhD (1) · Hande Seven Avuk, PhD (1) · Joseph Wu, PhD (1) · Marie Paule Schneider, Prof. PhD (1) · Marko Skelin, ass.prof.dr.sc, mag.pharm. (1) · Ross Tsuyuki, BScPharm, PharmD, MSc (1) · Yu Zhang, PhD (1)
2025 (1)